References
- Denning DS, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990;12:147-201
- Clinical practice guidelines in oncology. Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network (NCCN); 2009
- McCoy D, Depestel DD, Carver PL. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. Pharmacotherapy 2009;29:1306-25
- Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52
- Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51
- Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8. [Erratum, Br J Haematol 2006;132:665.]
- Simon A, Besuden M, Vezmar S, et al. Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem celltransplants. Support Care Cancer 2007;15:213-20
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
- Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138:705-13
- Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33
- Morgenstern GR, Prentice AG, Prentice HG, et al.; for the U.K. Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999;105:901-11
- Cecil JA, Wenzel RP. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Rev Hematol 2009;2:237-54
- Herbrecht R, Denning D, Patterson T, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2002;347:408-15
- Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42
- Marks DI, Pagliuca A, Kibbler C, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol 2011;155:1365-2141
- Jiang H, Zhou XH. Bootstrap confidence intervals for medical costs with censored observations. Stat Med 2004;23:3365-76
- Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis 2004;39:S200-6
- Johnson E, Gilmore M, Newman J, et al. Preventing fungal infections in immunocompromised patients. Br J Nurs 2000;9:1154-6, 1158–64
- Epstein JB, Truelove EL, Hanson-Huggins K, et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy. Support Care Cancer 2004;12:517-25
- Dixon S, McKeen E, Tabberer M, et al. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004;22:421-33